Generic Name and Formulations:
Praziquantel 600mg; scored tabs.
Indications for BILTRICIDE:
For the treatment of infections due to: all species of schistosoma, and infections due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini.
Adults and Children:
Swallow whole with water during meals. <4yrs: not established. ≥4yrs: Schistosomiasis: 20mg/kg 3 times daily as a one day treatment, at intervals ≥4hrs and ≤6hrs. Clonorchiasis, opisthorchiasis: 25mg/kg 3 times daily as a one day treatment, at intervals ≥4hrs and ≤6hrs.
Ocular cysticercosis. Concomitant strong CYP450 inducers (eg, rifampin).
Renal or moderate-to-severe hepatic impairment. History of epilepsy. Cerebral cysticercosis: hospitalize patient for duration of treatment. Monitor patients with cardiac irregularities. Possible clinical deterioration (paradoxical reactions, serum sickness Jarisch-Herxheimer like reactions). Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended and during subsequent 72hrs.
See Contraindications. Discontinue rifampin 4 weeks before giving praziquantel; may be restarted one day after completing praziquantel treatment. Potentiated by CYP450 inhibitors (eg, cimetidine, ketoconazole, itraconazole, erythromycin), grapefruit juice. Antagonized by CYP450 inducers (eg, phenytoin, phenobarbital, carbamazepine, dexamethasone).
Malaise, headache, dizziness, abdominal discomfort with or w/o nausea, fever, urticaria.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma